SectorBiotechnology Ⅲ
Established Date23/11/2020
Listing Date29/12/2022
ExchangeNASDAQ Stock Exchange
Full-time Employees8
Fiscal Year Ends31/12
Security TypeCommon stock
Office address5850 San Felipe St.
Suite 500
Houston
TX 77057
BusinessDevelops therapies for neurodegenerative, autoimmune and metabolic diseases.
IntroductionCoya Therapeutics, Inc., was incorporated under the laws of the State of Delaware on November 23, 2020. The company is a clinical-stage biotechnology company focused on developing patented drugs to regulate the function of sex T cells. Tregs is a subset of T lymphocytes composed of CD4 + CD25 high hFOXP 3 + cells that inhibit inflammation. Tregs and their transcription factors are essential for maintaining homeostasis by regulating autoimmune and inflammatory responses and maintaining mammalian self-tolerance. Treg dysfunction is an important part of the pathophysiology of severe neurodegenerative diseases, autoimmune diseases and metabolic diseases, and the company believes that there is an urgent need for new and effective treatments.
